source
- Glenmark agrees to $29.6 million settlement over generic drug price-fixing claimsGlenmark Pharmaceuticals has reached a settlement with dozens of U.S. states, agreeing to pay $29.6 million to resolve accusations that it participated in a scheme to inflate prices of generic medi…
- AdvanCell secures $315M Series D to advance lead-based prostate cancer therapyAdvanCell announced a $315 million Series D financing round aimed at supporting development of its lead-based prostate cancer agent and expanding U.S. manufacturing capacity for the radioactive tre…